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Acute graft pyelonephritis and long-term kidney allograft The main cause of kidney graft loss is chronic dysfunc-
outcome. tion, a multifactorial event in which an immunological
Background. Long-term graft function is the result of multi- component [1] and a combination of physiological over-ple parameters, including both immune and non-immune com-
load or initial poor quality of the transplant [2], metabolicponents, which have a beneficial or detrimental potential.
disorders (such as hyperlipidemia) [3], high blood pres-Among these, despite its frequency and theoretical interest
(expression of “danger signals” in the graft itself), the effects sure [4], and chronic exposure to nephrotoxic drugs have
of acute graft pyelonephritis (AGPN) on immediate and long- been shown to play a role. Association of independent
term outcome have not been studied in a large series. This factors such as delayed graft function (DGF) and thearticle reviews a cohort of 1387 consecutive primary renal trans-
presence of acute rejection episodes further reducesplant recipients.
long-term outcome [5]. Identifying the exact respectiveMethods. The objective of the study was to define the risk
factor for AGPN, the risk profile for recurrence, and the impact role of immunological and non-immunological factors is
of AGPN on long-term graft survival. According to a higher often not clinically possible. A significant proportion of
risk for AGPN in females during their follow-up, statistical long-term chronically “rejected” kidneys do not harboranalyses (Cox model, and multiple regression analysis) were
activated lymphocytes, even in the absence of immuno-performed by recipient sex strata.
suppressive drug administration [6], suggesting that theResults. Multivariate analysis showed that CMV infection
was the only risk factor for AGPN occurrence. AGPN occurred immune component of allograft dysfunction may be
in 13% of the graft recipients during their follow-up. Taken overestimated. Viral infection, such as cytomegalovirus
as a whole, AGPN was not associated with a significantly poor (CMV), also has been associated with poor long-termlong-term outcome. However, when assessed in more detail,
outcome although its impact recently was shown to bethe outcome of this population was found to be more complex
affected by antiviral prophylaxis [7] and by the combina-and to depend on several factors. Early AGPN (during the
first 3 months) was significantly detrimental for graft outcome, tion of mycophenolate mofetil (MMF) with antiviral
independently of acute rejection episodes. Moreover, E. coli drugs [8].
involvement in a first episode was linked to an increased AGPN Another complication that could potentially affectrecurrence.
long-term function is urinary tract infection complicatedConclusion. This analysis did not support the concept that
by acute graft pyelonephritis (AGPN), events that arewith current immunosuppression, strong “danger signals” such
as those derived from bacteria within an allograft, are instru- usual following transplantation. Indeed, AGPN can re-
mental in initiating acute or chronic rejection. sult in interstitial scars with a subsequent reduction in the
functional nephron mass. Furthermore, its occurrence
represents a theoretical risk of providing strong “danger
signals” [9], associated with bacterial products [10] di-1Both authors contributed equally to this study and are listed in alpha-
betical order. rectly within the graft, thus leading to (re)activation of
the host immune system against donor determinants andKey words: risk factors, chronic kidney rejection, acute rejection, im-
munosuppression, transplantation, bacterial infection. contributing to subsequent acute or chronic rejection.
Due to the lack of studies concerning the impact of
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patients who presented one or several episodes of specifically linked to the AGPN: (1) time of the first
AGPN (3 vs. 3 months), (2) type of bacteria impli-AGPN.
Our current report shows that the risk of AGPN corre- cated in the first AGPN (E. coli vs. all other types of
bacteria), (3) recurrence of AGPN episodes, and (4)lates with CMV infection. Taken as a whole, AGPN
was not associated with a poor long-term graft survival, presence of a vesicoureteral reflux (VUR).
however, early AGPN was linked to a decreased graft
Immunosuppressive regimenssurvival. Additionally, AGPN was not found to be associ-
ated with acute rejection episodes, a finding that does Since the study period spans more than a decade,
several protocols for induction and maintenance immu-not support the commonly held view that under current
immunosuppression therapies, strong danger signals can nosuppression were used. Sixty-three percent of the pa-
tients were treated from day one after surgery with aenhance host immune responses.
sequential induction [that is, delayed cyclosporine (CsA)
introduction] combining polyclonal antithymocyte glob-
METHODS
ulins (rabbit ATG or horse ALG; IMTIX-Sangstat,
Patients Lyon, France) or OKT3 (Orthoclone OKT3; N  9;
Janssen Cilag), azathioprine (2 mg/kg), or, since 1996,The aim for our study was to define which pre- and
post-graft parameters are risk factors for AGPN occur- mycophenolate mofetyl (MMF) 2 g/day. Corticosteroids
1 mg/kg/day were given to all patients and doses wererence, to evaluate the consequence of AGPN episodes
on long-term graft survival, and to investigate whether decreased by 10 mg every five days down to a dose of
10 mg/day, and withdrawn after three months of follow-different types of AGPN have differing effects on graft
outcome. A population of 1387 consecutive kidney graft up. CsA was introduced on day 10.7  5.7 (range 1 to
42), starting at a dose of 8 mg/kg/ day and then adjustedrecipients at our center from January 1987 to December
1999 was included in the study. All patients with func- to achieve blood trough levels between 150 and 250
ng/mL as measured by monoclonal radioimmunoassaytioning grafts had a minimal follow-up of one year. Pa-
tients were divided into two groups according to the [11]. Since 1995, this ATG induction therapy was re-
stricted to patients considered to be at high immunologi-presence (AGPN group) or the absence (no AGPN
group) of at least one episode of AGPN. The AGPN cal risk or have DGF (that is, with anti-T PRA 25%,
CIT36 hours, or recipients of multiple grafts). Azathio-group consisted of 180 patients and the 1207 remaining
patients were allocated to the no AGPN group. All clini- prine and MMF doses were adapted according to white
blood cell counts. Thirty-five percent of the patients (Ncal and biological data were recorded according to a
standardized “DIVAT network” (Donne´es Informati- 493) received either a sequential induction with mono-
clonal antibodies against CD4 [12], interleukin-2 recep-se´es et VAlide´es en Transplantation) procedure. A spe-
cialized clinical research assistant, who was independent tor (IL-2R) [13], leukocyte function associated antigen-1
(LFA1) [14], or a triple regimen of cyclosporine A, ste-of the medical team, computerized the pre- and post-
graft parameters of each patient transplanted in our cen- roids and either azathioprine or MMF without induction.
Among them, 50 patients received a peptide derivedter. Recorded data were submitted to an annual medical
audit with a level of error remaining below 1%. from the HLA-B2702 (Allotrap) [15] during the first
ten days following transplantation. Finally, 15 patients
Studied parameters (1%) received a deoxyspergualin analog (LF08) for
seven days. All patients were treated with an antibiopro-The pre-graft parameters analyzed were: (1) donor
and (2) recipient age (55 vs.55 years old), (3) gender, phylaxis with Bactrim (Trimethoprim-Cotrimoxazol)
during the first three months for the prevention of the(4) cadaveric or living related donor, (5) number of kid-
ney transplantations (2 vs. 2), (6) recipient initial Pneumocystis carinii.
disease (that is, urological malformations were pooled
Definition of acute graft pyelonephritisand compared with all other diseases), (7) HLA-A-B-
DR incompatibilities (1 incompatibility vs. 1), (8) Acute graft pyelonephritis was defined by the associa-
tion of fever with one or more of the following clinicalpanel reactive anti-T antibodies (PRA; 25 vs. 25%)
and (9) cold ischemia time (CIT; 36 vs. 36 hours). symptoms or biological abnormalities: painful graft, chills,
cystitis, dysuria, leukocyturia, pyuria, bacteriuria and in-Medical events that occurred throughout the follow-up,
designated post-graft parameters, were: (1) induction creased creatinemia. If bacteriuria was not proved due
to technical reasons, patients who were treated and re-therapy with either ATG, ALG or OKT3; (2) occurrence
of one or more acute rejection episodes (defined later sponded to an antibiotic therapy course were included in
the study as “intended-to-treat” patients. An associationin this article); and (3) occurrence of a CMV infection
(defined later in this article). Finally, other parameters of two antimicrobial agents was used according to antimi-
crobial susceptibility, first, intravenously until apyrexia,were studied in the AGPN population including those
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then orally for at least three weeks. In the case of recur- died during the study period were considered as trans-
plant failure. All tests and confidence limits were per-rent episodes of AGPN, a local consensus recommended
urological exploration looking for a vesicoureteral reflux formed at an alpha risk of 5%.
(VUR) but not for a single episode. The immunosup-
pressive regimen was not modified in the case of one
RESULTS
AGPN or recurrence.
Female recipients are at a higher risk of AGPN
Surgical procedures Thirteen percent of recipients experienced at least one
AGPN episode during their follow-up. The incidence ofA ureteral stent was not systematically used during
graft surgery, except in the case of poor quality of the AGPN did not change over time during the study pe-
riod: 12.8% (1987–1991), 13.7% (1992–1995), and 12.2%ureter or the bladder.
(1996–1999). There was no difference in the demo-
Definition of acute rejection episodes graphic characteristics between the AGPN group (N 
180) and the no AGPN group (N  1207) as shown inAcute rejection episodes (AREs) were diagnosed on
the grounds at least of clinical symptoms and were con- Table 1, except for gender: 65% of females in the AGPN
group and 38% in the no AGPN group (P  0.0001).firmed by graft biopsy examination. In a few cases, biopsy
sampling was not technically possible and “intended-to- Accordingly, we tested the pre- and post-graft parame-
ters in the Cox model by “recipient sex” strata, to definetreat” episodes that responded to the treatment also
were taken into account. AREs treatment consisted of which independent variables could be associated with
the occurrence of a first AGPN episode.intravenous corticosteroid (Solumedrol; Upjohn, Paris,
France) boluses for five consecutive days, followed by
Risk profileATG in the event of corticosteroid resistance (that is,
stable or increased blood creatinine after the last bolus Patients who experienced a CMV infection (P 0.02)
had an increased risk of AGPN (Table 2). Fifty-threeand the absence of histological improvement).
patients (3.8%) presented both CMV infection and
Definition of CMV infection AGPN. In the majority of cases (67%) AGPN occurred
after CMV infection, whereas it occurred before CMVCytomegalovirus infection was defined as the associa-
tion of fever with one or more of the following clinical in 25% and at the same time in 8%. Figure 1 shows
the time sequence of the occurrence of the first AGPNsymptoms or biological abnormalities: leukopenia, gas-
trointestinal disease, pancreatitis, hepatitis, pneumonitis, episode as compared to CMV infection episodes.
The incidence of acute rejection (AREs) did not differnephritis and/or myalgia/arthralgia. Virological proof of
CMV infection was obtained in all patients by rapid between the two groups: 27% of acute rejection episodes
were observed in the AGPN group and 28% in the noviremia ( viruria), seroconversion, qualitative DNA
polymerase chain reaction (PCR) testing, or histological AGPN group. When both events (that is, AREs and
AGPN) occurred in a patient, AGPN occurred after theevidence of endothelial cell inclusion of viral particles.
Eighty percent of patients were treated with Gancyclo- ARE episode in 80% of the cases (Fig. 2). These results
suggest that the risk of AGPN may be linked to an over-vir. No CMV prophylaxis was administered in this co-
hort. immunosuppression and do not support the hypothesis
that AGPN triggers CMV infection or ARE.
Statistical method
Recurrence of AGPNSeveral questions were addressed in this study. (1)
What are the risk factors for AGPN? (2) What is the risk One third of patients (N  57) had more than one
episode of AGPN. To define the risk factors of AGPNprofile in patients with recurrent AGPN? (3) Is AGPN a
risk factor for graft loss? (4) Do some AGPN characteris- recurrence, we performed a logistic regression in patients
who experienced at least one AGPN episode. Given thetics (time of occurrence of the first episode, type of bacte-
ria, recurrence) have a specific impact on long-term graft relatively small size of the patient sample, only tests and
confidence limits at an alpha risk of 1% were consideredoutcome? When necessary the Cox proportional hazard
regression was used to estimate relevant risk factors. significant. We compared pre- and post-graft parameters
according to the occurrence of only one AGPN or moreKaplan-Meier analyses were performed in order to ob-
tain additional descriptive curves and univariate log-rank than one (which defined the recurrence). As shown in
Table 3, the type of bacteria involved in the first episodestatistics. A logistic regression was performed to assess
the risk profile of AGPN recurrence. In addition, be- was significantly and independently correlated with
AGPN recurrence. Indeed, first AGPN episodes werecause of a strong bias of recipient sex ratio in patients
with AGPN and those without AGPN, we performed less often linked to Escherichia coli in patients with only
one AGPN episode (53%) than in patients with recur-these analyses by “recipient sex strata.” Patients who
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Table 1. Demographic characteristics according to the presence or the absence of AGPN
AGPN (N  180) No AGPN (N  1207) P value
Recipient age years (range) 43.314 (15–71) 44.913 (15–73) NS
Donor age years (range) 36.215 (1–66) 3715 (1–70) NS
Male donors 119 (66.1%) 846 (70.1%) NS
Male recipients 69 (38.3%) 785 (65.0%) 0.0001
Recipient age 55 years 136 (75.6%) 892 (73.9%) NS
Donor age 55 years 160 (88.9%) 1050 (87.0%) NS
Cadaver donor 172 (95.6%) 1158 (95.9%) NS
Number of grafts 2 172 (95.6%) 1164 (96.4%) NS
Initial diseasea 31 (17.2%) 171 (14.2%) NS
anti T PRA 25% 70 (38.9%) 458 (37.9%) NS
HLA-A-B-DR inc. 1 29 (16.1%) 157 (13.0%) NS
CIT 36 h 70 (38.9%) 506 (41.9%) NS
ATG/ALG/OKT3 induction 112 (62.2%) 801 (66.4%) NS
Acute rejection episodes 0 55 (30.6%) 340 (28.2%) NS
CMV infection 53 (29.4%) 285 (23.6%) NS
Abbreviations are: AGPN, acute graft pyelonephritis; PRA, panel reactive antibodies; HLA, human leukocytes antigen; CIT, cold ischemia time; ATG/ALG/
OKT3, polyclonal antithymocyte globulins/or anti CD3 monoclonal antibody; CMV, cytomegalovirus.
a Urological diseases versus others
Table 2. Cox model analysis: Risk factors for a first AGPN episode Impact of AGPN on long-term graft survival
95% Confidence The ten-year Kaplan-Meier graft survival of the whole
limits population was 60% when death was censored and 72%
Parameters Risk ratio P value Lower Upper without death. Due to the high frequency of AGPN in
CMV infection 1.497 0.02 1.072 2.089 female recipients (see above), all parameters were then
ATG/ALG/OKT3 induction 0.725 NS 0.523 1.007 tested in the Cox model by “recipient sex strata.” SeveralInitial diseasea 1.128 NS 0.756 1.682
independent expected parameters were significantly as-anti T PRA 25% 0.911 NS 0.657 1.262
Acute rejection episodes 0 1.028 NS 0.732 1.442 sociated with graft loss: multiple grafts 2 (RR  0.537,
CIT 36 h 1.116 NS 0.806 1.547
CI 0.3–0.9, P  0.01); HLA-A-B-DR incompatibilitiesDGF 10 days 0.976 NS 0.688 1.384
HLA-A-B-DR inc. 1 0.788 NS 0.506 1.226 1 (RR  0.734, CI 0.5–1, P  0.05); donor age 55
Donor relationship 1.382 NS 0.618 3.092 years (RR 1.451, CI 1–1.9, P 0.01); recipient age55Number of grafts 2 0.942 NS 0.398 2.231
years (RR 1.813, CI 1.4–2.3, P 0.0001); occurrence ofDonor sex 1.214 NS 0.877 1.679
Donor age 55 years 1.001 NS 0.611 1.639 one or more acute rejection episodes (RR  2.340, CI
Recipient age 55 years 0.824 NS 0.570 1.193 1.9–2.9, P  0.0001), and patients who experienced a
CMV infection is an independent risk factor for the occurrence of AGPN. CMV infection (RR  1.399, CI 1.1–1.8, P  0.005).a Urological diseases versus others
Interestingly, AGPN did not appear to be a significant
independent factor influencing graft survival in the whole
population (Fig. 3).
rence of AGPN (84%; P  0.0001). The other bacteria
involved in the first episodes of AGPN in the cases of All AGPN have not the same impact on long-term
recurrence were (N  1) Klebsiella, (1) Serratia, (2) graft survival
pyocyanics, (2) streptococcus, and (3) unidentified. How-
A Cox model analysis was performed in patients whoever, recurrent AGPN appeared significantly more often
presented one AGPN episode to determine whetherin females (72% recurrent AGPN vs. 57% single episode;
some types of AGPN could have an impact on graftP  0.05). Although urological surgical complications
survival. In this model, all described variables were(ureteral stenosis or necrosis) occurred in 10.8% of the
tested by “recipient sex” strata. As expected, acute rejec-whole population, the recurrence of AGPN was never-
tion episodes (RR  6.7, CI 2.5–8.5, P  0.0002) was atheless not significantly higher in patients who presented
major risk factor for graft loss as well as induction treat-early urological complications after surgery (hematoma,
ment with either ATG/ALG/OKT3 (RR  3.7, CI 1.4–ureteral necrosis or stenosis; 19%) than in patients who
9.7, P  0.008) specifically used since 1996 in “at riskhad no recurrence (14%; PNS). Moreover, vesicoure-
patients or in patients presenting a DGF” (Patients sec-teral reflux (VUR) was radiologically proven in 47% of
tion in the Methods). However, besides the classical vari-patients with recurrent AGPN. However, this cannot be
ables, interestingly, occurrence of the first AGPN epi-compared with its frequency in patients with only one
sode during the first three months (30.5%) was also aAGPN because a local consensus does not recommend
this type of investigation for VUR for a single AGPN. highly significant independent risk factor for graft loss
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Fig. 1. Timing of the first acute graft pyelone-
phritis (AGPN) episode compared to the first
cytomegalovirus (CMV) infection during the
follow-up. Sixty-seven percent of AGPN oc-
curred after CMV infection and only 33% be-
fore or at the same time. Each bar represents a
patient with a first AGPN and CMV infection.
Fig. 2. Timing of the first acute rejection epi-
sode (ARE) occurrence as compared to that
of the onset of AGPN episodes (in days) dur-
ing the follow-up. Eighty percent of the first
AGPN episodes occurred after the first ARE.
Each bar represents a patient with a first
AGPN and an acute rejection episode.
Table 3. Logistic regression: Risk factors for AGPN recurrence (comparison of risk factors for one AGPN vs. more than one)
Parameter Standardized
Variables estimate P value estimate Odds ratio
Recipient age 0.5735 NS 0.134835 1.774
Recipient sex 0.4199 NS 0.112775 0.657
Time to 1st AGPN 0.2567 NS 0.122322 1.293
1st AGPN with E. coli 1.9724 0.0001 0.526523 0.139
Induction treatment 0.9458 NS 0.253281 2.575
Initial diseasea 0.7741 NS 0.164149 2.169
Anti-T PRA level 0.0809 NS 0.021798 0.922
CMV infection 0.3945 NS 0.100006 1.484
Acute rejection episodes 0.9236 NS 0.235422 0.397
Cold ischemia time 0.3570 NS 0.096151 0.700
HLA incompatibilities 0.4400 NS 0.088287 0.644
Number of grafts 0.6855 NS 0.069349 0.504
Donor age 0.00961 NS 0.079141 1.010
Donor sex 0.0354 NS 0.009241 0.965
Donor relationship 1.0922 NS 0.118999 0.335
The type of bacteria involved in the first episode of AGPN other than E. coli was an independent risk factor linked significantly linked to multiple episodes of
AGPN.
a Urological diseases versus others
(RR  3.6, CI 1.4 – 9.2, P  0.007). Figure 4 also shows population is in this study was heterogenous and several
risk and prognostic factors were identified. Long-termthe Kaplan-Meier graft survival according to the onset
graft dysfunction is the primary cause of graft loss [16].of the first AGPN episode.
If it is well established that the incidence of urinary tract
infections is a frequent event (30%) in the first three
DISCUSSION months after transplantation with a high risk of pyelone-
This report shows that on the whole, AGPN is not phritis [17, 18], this incidence may increase further in
the future with the strength of immunosuppression.associated with poor long-term outcome. However, the
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Fig. 3. Kaplan Meier analysis of graft survival according to the presence Fig. 4. Kaplan-Meier analysis of graft survival according to the time
of at least one AGPN episode (dashed line; N  180) or no AGPN of occurrence of the first AGPN episode, before (dashed line; N  92)
(solid line; N  1207). AGPN is not a significant risk factor for graft or after (solid line; N  88) three months. Early AGPN is a risk
loss. factor for graft loss and confirmed to be independent of other tested
parameters when tested in the Cox model analysis.
However, to date no study has been specifically devoted
and expression of M adhesin. Accordingly, an efficientto the impact of graft pyelonephritis on graft outcome,
prevention of urinary infection during the first threein large kidney graft recipient cohorts. AGPN is a fairly
months following transplantation [17] could be recom-frequent complication of kidney transplantation, affect-
mended as well as early catheter removal [22], systematicing 13% of the entire transplanted population, and
examination for reflux at the first AGPN, and preventionreaches an incidence of 21% in women. Thus, AGPN in
of recurrent infections by long-term antimicrobial pro-women is approximately as frequent as CMV infection
phylaxis [19].(19.6%) or even acute rejection (29.6% in the same fe-
Special attention must be paid if the first AGPN ismale cohort). This strong gender bias was the rationale
due to E. coli or if the first episode of AGPN occurs
for focusing our multivariate Cox analysis on the female
early after surgery. However, the opposite and poten-
cohort of graft recipients. tially pejorative effect of selecting multi-resistant anti-
Our study demonstrates that AGPN appears to repre- bacterial drugs makes a firm recommendation for this
sent several clinical entities associated with different therapy difficult.
prognoses according to parameters such as the time of Another unexpected finding of this study was that
AGPN occurrence and the bacteria involved. Interest- the occurrence of AGPN was not associated with an
ingly, when the associated parameters were tested in a increased incidence of acute rejection (or chronic rejec-
Cox model, AGPN episodes appeared to occur more tion onset) in the multivariate analysis and did not initi-
often in patients who experienced CMV infection. This ate graft rejections. In fact, the impact of AGPN on long-
suggests that AGPN could be linked to an over-immuno- term function appeared to be related more to the direct
suppression rather than that it triggers CMV activation deleterious effect of bacteria, possibly linked to the uro-
[19]. Active reflux has long been reported as being sig- logical prothesis and/or nosocomial infection during the
nificantly associated with poor graft outcome [20]. How- early post-transplantation period. However, interest-
ever, we could not assess the frequency of VUR in all ingly, in our case-by-case study on the 180 AGPN pa-
of the patients because cystography was restricted to tients, only very rare acute rejections were observed
only those who presented at least two episodes of AGPN following the acute bacterial infection episodes. This
during their follow-up. suggests that “danger” signals could not be as important
Therefore, despite the finding that the analysis of the (in the current immunosuppression conditions) as pre-
impact of AGPN performed on the entire recipient co- viously thought or that some regulatory mechanisms that
hort does not appear to be significantly detrimental, take place following transplantation [23], are efficient.
more detailed studies show that a complex pattern of Finally, the fact that AGPN episodes that do not occur
clinical presentation exists and readily identify pejora- in the context of the specific risk factors identified (CMV,
tive associations that require special clinical attention. strong induction) are associated with a remarkable long-
Among these and in agreement with some recently pub- term graft outcome also suggests the possibility that they
lished data is the suggestion that low virulent E. coli occur in patients with a “low responder phenotype” re-
strains may cause urinary tract infection (UTI) more sponsible for both the occurrence of urinary tract infec-
frequently in immunocompromised patients [21], possi- tion and the decreased incidence of chronic rejection.
However, the facts that these patients did not show ably because of a lower prevalence of G adhesin genes
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but prevents CMV induced chronic graft dysfunction. J Am Soccontradicts this hypothesis.
Nephrol 12:1758–1763, 2001
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